Tango Therapeutics (NASDAQ:TNGX) stock plunged 28% in morning trading Wednesday after the company announced updates on several drug candidates and released its Q3 earnings report. Tango said it was ...

Data update from the TNG462 Phase 1/2 trial is expected in 2H 2025, which may provide significant insights into its efficacy, safety, and tolerability in treating pancreatic and lung cancer.

BOSTON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer ...

– TNG462 demonstrated durable clinical activity across multiple tumor types, including non-small cell lung cancer (NSCLC) and pancreatic cancer, in ongoing phase 1/2 clinical trial, moving into full ...

Tango Therapeutics ( ($TNGX) ) has shared an announcement. On January 2, 2026, Tango Therapeutics, Inc. expanded its Board of Directors from seven ...